The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
@RiskIsReward: The webpage you are looking at is outdated and not updated. The POC kit was designed to to have a positive result in 15mins and a negative result in 20mins. You can confirm this by referring to both presentations (Nov and Mar) and in the Results RNS' as well.
My only bit of advice would be to not be ahead of the finish, with regards to DIVOC and our current relationship. I say this based on 2 items:
1) Recently I have been in contact with Walbrook and got replies. However my last question about our current relationship with DIVOC has not been answered.
2) I have been involved in Marketing and PR - and in regards to news articles not all the time do you get privy to view the article before release. Why I raise this point, is that the last line "To address the immediate need for India to possess access to high-quality COVID19 Tests DIVOC is bringing GeneDrive RT PCR COVID19 Tests to India" has been used in a couple other articles AND while small, they keep spelling GDR incorrectly - capitalising the 'D'.
I do hope that if we are not using DIVOC anymore, that we have either via BC or another effective distributor, been working some potential deals.
@Pacman121: thanks for the reply. Yes, your point raised a new angle as to what could be happening - that's what sparked my interest in your statement. We know that BC don't release their numbers unless they really want to and GDR are very coy in communicating anything to us. So to support these two scenarios it could well be that direct sales are occurring between Cytva and BC. Wishful thinking or reality, who knows!!!
Pacman121: nice write up! I can agree with the call for:
1) Change at the board level and a more structured and formal communication strategy (as opposed to the subjective adhoc approach now employed).
2) Revision of bonus structure to be one aligned with revenue/profit and/or other transparent and measurable KPIs.
One question I have is to the accuracy of your statement that BC can/are ordering directly from Cytiva and therefore are able to by-pass GDRs , thus allowing GDR to remain silent and support BC's mute status on their numbers?
I was told by Walbrook that we may get an update in July
I agree with Dave re: the 11th hr notification of the POC delay which would have been known well in advance.
I would be curious to the response if someone else put the question (why can't we have quarterly updates) to Walbrook. When I asked in April I was simply told my comments would be forwarded to the GDR team.
But its ridiculous that we have 2 presentations a year and then we speculate the life out of this company in between. The notion of "we update when we have material news" , should be applicable to all aspects - sales, commercial partnerships, new products, approvals and delays, dead deals etc.
1) "You noticed BC have a genedrive type product". What do you mean by this?
2) I'm not sure what you know about Genedrive as we don't only have one product. But that aside, are trying to say BC have FDA approval for a PCR test? If so, Im not sure where you see that, so please provide more info
3) Did you read our RNS on 9th March to understand what the BC partnership means?
Where do we stand?
1) Does our PCR test have any short-term (1-3months) sales conversions in advanced stages - in any of our approved countries i.e. UK, EU, India, South Africa, Thailand, Malaysia?
2) Have we shipped any more products to BC? (If BC are private and therefore work to a different beat, GDR is public and therefore shall advise the market of their sales)
3) Is the non-EUA access to the US market working at present via BC?
4) Is there a Plan B/C/D…. for US FDA EUA?
5) Is the EU MoH now a dead duck.
6) Is the POC launching in the next 3 weeks, to remain within the revised Q2 target?
For FDA EUA approval, there is no requirement to send sample tests or tests for in-house trials. The FDA assess data provided by the company (for which I believe US lab becomes key, which we have) . This has been confirmed twice by David and Walbrook.